{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-012295","form_type":"8-K","ticker":"QURE","cik":"0001590560","company_name":"uniQure N.V.","filed_at":"2024-08-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.673601+00:00","generated_at":"2026-05-31T09:00:46.034893+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"uniQure doses first patient in Phase I/IIa AMT-191 Fabry disease trial","bullets":["First patient dosed in open-label, two-cohort Phase I/IIa trial of AMT-191 gene therapy for Fabry disease.","Low-dose cohort: 6e10^13 gc/kg; high-dose: 3e10^14 gc/kg; one-time IV infusion; 24-month follow-up.","AMT-191 uses same AAV5 delivery as HEMGENIX; targets liver to produce GLA protein.","CEO cites catalysts: FDA engagement for AMT-130 (Huntington's), new trials in epilepsy and SOD1-ALS.","Cash runway extended through end of 2027 from cost reduction initiatives."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-012295","json":"https://secwatch.observer/filing/0001558370-24-012295.json","markdown":"https://secwatch.observer/filing/0001558370-24-012295.md","text":"https://secwatch.observer/filing/0001558370-24-012295.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590560/000155837024012295/0001558370-24-012295-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590560/000155837024012295/qure-20240815x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:00:46.034893+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}